Risk | Moderately High |
---|---|
Min SIP Amount | Not Supported |
Expense Ratio | 1.36% |
NAV | ₹10.25 (06 Oct 2020) |
---|---|
Fund Started | 28 Sep 2017 |
Fund Size | ₹357 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Infosys Ltd. | Technology | Equity | 3.0% |
ITC Ltd. | FMCG | Equity | 1.7% |
ICICI Bank Ltd. | Financial | Equity | 1.5% |
Axis Bank Ltd. | Financial | Equity | 1.0% |
Eicher Motors Ltd. | Automobile | Equity | 1.0% |
Ipca Laboratories Ltd. | Healthcare | Equity | 1.0% |
National Thermal Power Corp. Ltd. | Energy | Equity | 1.0% |
ICICI Prudential Life Insurance Company Ltd. | Financial | Equity | 1.0% |
Cipla Ltd. | Healthcare | Equity | 1.0% |
Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 1.0% |
UTI Focussed Equity Fund Series IV (1104 Days) Regular Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 28 Sep 2017. Vetri Subramaniam, Sachin Trivedi is the Current Fund Manager of UTI Focussed Equity Fund Series IV (1104 Days) Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹357 Cr and the Latest NAV as of 06 Oct 2020 is ₹10.25.
The UTI Focussed Equity Fund Series IV (1104 Days) Regular Growth is rated Moderately High risk.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of listed companies. The scheme will without any capitalization bias endeavour to invest in either growth stocks or value stocks or both. The Scheme will normally hold upto 30 stocks in the portfolio.